Skip to main content
padlock icon - secure page this page is secure

Ibopamine Stimulates α-Adrenergic Receptors and D1 Dopaminergic Receptors in the Eye

Buy Article:

$68.00 + tax (Refund Policy)

Ibopamine stimulates α-adrenergic receptors and D1-dopaminergic receptors in the eye. Ibopamine is a dopamine analogue and it is hydrolysed to epinine by the esterases in the aqueous humor. Adrenergic stimulation determines the non-cycloplegic mydriatic effect, while the D1-dopaminergic activity is responsible for an increase in aqueous humor production. Ibopamine is effective as a mydriatic before and after surgical procedures. Its main uses are: provocative test in glaucoma; treatment of ocular hypotony; evaluation of the outflow pathways of the aqueous humor. Ibopamine test is positive in 92% of patients affected by primary open-angle glaucoma (POAG), while it is negative in healthy eyes. It is useful in relatives of glaucomatous patients.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Ibopamine; diagnostic test; dopaminergic drugs; glaucoma; non-cycloplegic mydriatic; ocular hypotony

Document Type: Research Article

Affiliations: Lecturer in Ophthalmology, Medical School, University of Roma “Tor Vergata”, Via Seneca, 34, 00136 Roma, Italy.

Publication date: May 1, 2007

More about this publication?
  • Current Drug Therapy publishes frontier reviews on all the latest advances in drug therapy. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: new and existing drugs, therapies and medical devices.

    The journal is essential reading for all researchers and clinicians involved in drug therapy.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more